A case report of targeted therapy with apatinib in a patient with recurrent high grade glioma

Medicine (Baltimore). 2018 Jun;97(22):e10859. doi: 10.1097/MD.0000000000010859.

Abstract

Rationale: Despite the approval of antiangiogenic therapy for high grade glioma (HGG) patients, survival benefits are still limited. New treatment plans have always been developed to improve the survival.

Patient concerns: A 26-year-old woman was admitted to our hospital for distending pain of head and eye.

Diagnoses: Resonance imaging (MRI) revealed a large spherical heterogeneously enhancing, mixed cystic and solid mass in the right frontal region, and the midline shifted.

Intervention: The patient received apatinib therapy for positive vascular endothelial growth factor.

Outcomes: A partial response was observed after 4 weeks and remains sustained until now.

Lessons: It suggests that apatinib might be a feasible option for the treatment in advanced HGG patients or patients with poor physical condition.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Brain Neoplasms / chemistry
  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / drug therapy*
  • Female
  • Frontal Lobe / diagnostic imaging
  • Glioma / chemistry
  • Glioma / diagnostic imaging
  • Glioma / drug therapy*
  • Humans
  • Magnetic Resonance Imaging
  • Neoplasm Grading
  • Neoplasm Recurrence, Local / chemistry
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / drug therapy*
  • Pyridines / therapeutic use*
  • Vascular Endothelial Growth Factor A / analysis

Substances

  • Antineoplastic Agents
  • Pyridines
  • Vascular Endothelial Growth Factor A
  • apatinib